The Use of Biomarkers in Early-Stage NSCLC

H&O Should patients with early-stage non–small cell lung cancer (NSCLC) get biomarker testing of their surgical specimens? JK A few years ago, I would have said […]

Biomarkers for Immune Therapy in Gastrointestinal Cancers

Abstract: Immunotherapy with checkpoint blockade of pro-grammed death 1 (PD-1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has substantially increased the number of anticancer agents in […]

New Treatments for Stage I Testicular Cancer

Abstract Clinical stage I represents the most frequent presentation of both seminoma and nonseminoma testicular cancer. Despite a survival rate of close to 100%, the […]